Expansion Potential HelloBetter has a growing international footprint, with US market entry for HelloGina and ongoing partnerships like the Generali Mein MentalHealthCoach initiative, presenting cross-border sales opportunities for digital mental health solutions and B2B collaborations.

Evidence-Backed Advantage With the strongest global evidence base and 33 randomized controlled trials, HelloBetter can leverage its clinical credibility to position PDTx products to healthcare providers, payers, and DiGA adopters seeking proven digital therapeutics.

Strategic Partnerships Recent collaborations with Generali Health Solutions and PREVENT.ON indicate a clear appetite for enterprise partnerships in corporate and insurance channels, suggesting opportunities to sell white-labeled or co-developed DTx solutions.

FDA Recognition Breakthrough Device Designation for HelloBetter Panic signals regulatory momentum and potential for accelerated adoption in the US market, enabling targeted outreach to US health systems, clinics, and pharma-affiliated networks.

Financial Momentum Multiple funding rounds totaling over €37M and ongoing revenue in the low-to-mid single digits in USD position HelloBetter for scaled commercial efforts, fundraising-backed go-to-market investments, and larger deal opportunities with healthcare organizations.